Connor, Clark & Lunn Investment Management (CC&L)’s Entrada Therapeutics TRDA Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio TRDA Stock Details TRDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-11,553	Closed	-$104K	–	1687
2025 Q1	$104K	Sell	11,553 -74,068	-87%	-$923K	﹤0.01%	1350
2024 Q4	$1.48M	Sell	85,621 -52,984	-38%	-$960K	0.01%	812
2024 Q3	$2.21M	Buy	138,605 +78,953	+132%	+$1.24M	0.01%	644
2024 Q2	$850K	Buy	59,652 +28,868	+94%	+$410K	﹤0.01%	888
2024 Q1	$436K	Buy	+30,784	New	+$435K	﹤0.01%	1154

Other funds holding TRDA

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s TRDA Position: Q2 2025 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Entrada Therapeutics (TRDA) in Q2 2025, closing a stake of 11,553 shares — an estimated $104K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in TRDA in Q1 2024 and held it in 5 quarters. The position peaked at $2.21M in Q3 2024. 107 funds tracked by Wall St. Rank hold TRDA as of Q2 2025.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Entrada Therapeutics position as of Q2 2025 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 11,553 Entrada Therapeutics shares in Q2 2025, an estimated $104K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Entrada Therapeutics in Q1 2024 and held it in 5 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Entrada Therapeutics position peaked at $2.21M in Q3 2024.
107 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2025.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2025, filed 7 Aug 2025.